Poor adherence to protocol and regulatory requirements 3. Incidence or severity of adverse drug reaction in this or other studies indicates a potential health hazard to subjects 4. Plans to modify or discontinue the development of the study drug In the event of BMS decision to no longer supply study drug, ample notification will be provided so that appropriate adjustments to subject treatment can be made. Protocol: Version 8.0.